. 2021 Aug 31;12:662856. doi: 10.3389/fneur.2021.662856

Table 11.

Additional comparative adverse event data for TPE in MG.

References	Gajdos et al. (41)	Barth et al. (5)	Qureshi et al. (42)	Murthyet al. (47)	Köhler et al. (52)	Trikha et al. (65)	Liew et al. (25)	Rønager et al. (45)	Saeteng et al. (56)	Mandawat et al. (1)	Citterio et al. (71)	Guptill et al. (62)	Mandawat et al. (63)
Treatment context	Acute	Acute	Acute	Acute	Acute	Acute	Chronic	Chronic	Peri-op	Mixed	Mixed	Mixed	Mixed
												TPE	TPE
Comparison	TPE/	TPE/	TPE/	TPE/	TPE/	TPE QD/	TPE/	TPE/	TPE/	TPE/	TPE/	peripheral	early/
	IVIG	IVIG	IVIG	IVIG	lA	TPE QAD	IVIG	IVIG	No TPE	IVIG	IVIG	/TPE	TPE
												central^**	delayed
Timing	15 days	30 days	hosp.	Tx	Tx	hosp.	1 yr^*	16 wk	hosp.	hosp.	14 yrs^*	Tx	hosp.
Patients	41/46	41/40	28/26	15/8	10/9	16/17	20/17	12/12	33/53	1,269/340	318/176	100/34	870/183
Renal Failure	-	-	-	-	-	-	-	-	-	5/1%^∧	-	0/9%^∧	1/4%^∧
Hypokalemia	-	-	-	-	10/11%	-	-	-	-	-	-	-	-
Elevated BUN	-	-	0/8%	0/13%	-	-	-	-	-	-	-	-	-
Fever	5/0%	0/8%	-	-	30/0%	-	0/10%	0/33%	0/0%	-	-	-	-
Chills	5/0%	0/5%	-	-	-	-	-	-	-	-	-	-	-
Headache	0/2%	0/20%^∧	-	-	-	-	-	0/58%^∧	-	-	-	-	-
Nausea and vomiting	2/0%	0/18%^∧	-	-	-	-	-	0/25%	-	-	-	-	-
Allergic reaction	-	0/5%	-	-	10/0%	6/0%	-	-	0/0%	-	-	-	-
Citrate reaction	-	15/0%^∧	-	-	-	-	-	-	-	-	-	-	-
Extrathymic tumor	-	-	-	-	-	-	-	-	-	-	8/14%	-	-

hosp., during hospitalization; Tx, during treatment period; IA, immunoadsorption. No significant difference observed between treatments (p ≥ 0.05) unless noted.

^∧

p < 0.05 as reported by original authors or calculated using Fisher exact test.

(25) median 1 yr follow-up (range 0–5 yrs), (71) 14 yr mean follow up across all patients.

^**

peripheral venous access and central venous access.